← Back to Screener
Cognition Therapeutics, Inc. Common Stock (CGTX)
Price$1.12
Favorite Metrics
Price vs S&P 500 (26W)-43.72%
Price vs S&P 500 (4W)1.72%
Market Capitalization$106.33M
All Metrics
Book Value / Share (Quarterly)$0.39
P/TBV (Annual)0.76x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.28
Price vs S&P 500 (YTD)-15.99%
EPS (TTM)$-0.34
10-Day Avg Trading Volume0.97M
EPS Excl Extra (TTM)$-0.34
EPS (Annual)$-0.32
ROI (Annual)-68.53%
Cash / Share (Quarterly)$0.41
ROA (Last FY)-48.54%
EBITD / Share (TTM)$-0.32
ROE (5Y Avg)-86.22%
Cash Flow / Share (Annual)$-0.28
P/B Ratio3.10x
P/B Ratio (Quarterly)3.48x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-1805.69x
ROA (TTM)-69.64%
EPS Incl Extra (Annual)$-0.32
Current Ratio (Annual)3.45x
Quick Ratio (Quarterly)3.37x
3-Month Avg Trading Volume1.02M
52-Week Price Return218.86%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.95
52-Week High$3.83
EPS Excl Extra (Annual)$-0.32
CapEx CAGR (5Y)-50.89%
26-Week Price Return-34.97%
Quick Ratio (Annual)3.37x
13-Week Price Return-16.20%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.45x
Enterprise Value$69.521
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.41
3-Month Return Std Dev121.68%
Net Income / Employee (TTM)$-1
ROE (Last FY)-68.53%
Net Interest Coverage (Annual)-1426.46x
EPS Basic Excl Extra (Annual)$-0.32
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.34
ROI (TTM)-104.04%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.39
Price vs S&P 500 (52W)183.77%
Year-to-Date Return-11.85%
5-Day Price Return22.13%
EPS Normalized (Annual)$-0.32
ROA (5Y Avg)-59.30%
Month-to-Date Return56.68%
Cash Flow / Share (TTM)$-0.79
EBITD / Share (Annual)$-0.32
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-86.22%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.34
P/TBV (Quarterly)1.06x
P/B Ratio (Annual)3.48x
Book Value / Share (Annual)$0.39
Price vs S&P 500 (13W)-19.06%
Beta1.77x
Revenue / Share (TTM)$0.00
ROE (TTM)-104.27%
52-Week Low$0.22
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.10
4.10
4.10
4.10
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CGTXCognition Therapeutics, Inc. Common Stock | — | — | — | — | $1.12 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Cognition Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs for age-related degenerative diseases of the central nervous system and retina. Its lead candidate, CT1812, is an oral antagonist designed to cross the blood-brain barrier and selectively bind to the S2R complex. The company is advancing this approach through clinical development.